Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Pharmaceuticals Secures USD $1.9 Million Sales Contract for SmoothX 2% (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

CytoDyn Inc CYDY

Healthcare Biotechnology
CytoDyn Inc. is a clinical-stage biotechnology company. The Company is focused on the development and commercialization of leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells. The Company is studying leronlimab in multiple therapeutic areas, including infectious disease, cancer, and autoimmune conditions. Its core areas of clinical development are human immunodeficiency viruses (HIV), non-alcoholic steatohepatitis (NASH), and solid tumors in oncology. The areas of clinical focus in HIV are the lifting of the clinical hold, creation of a long-acting formulation of leronlimab and an HIV functional cure in using adenovirus vectors (AAV). In NASH, its focus is on the general population of those affected by NASH, and the subpopulation of patients with NASH and HIV. Regarding oncology, its focus remains on combination therapy for solid tumors.


OTCQB:CYDY - Post by User

CytoDyn Inc > Some traders on this stock
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2)
•••
Comment by tikotikoon Jul 04, 2020 11:05am
121 Views
Post# 31223921

RE:Some traders on this stock

RE:Some traders on this stock

Some weekend news: 1) deal made last Friday with pharmaceutical company with expertise on inyectable drugs, 2) CEO to appear in Dr. Been's YouTube broadcast today, and 3j Rumors from NBC news that White House will announce more focus on therapeutics to fight COVID (Leronimab possibly?)

https://www.cytodyn.com/newsroom/press-releases

 

https://www.nbcnews.com/politics/politics-news/we-need-live-it-white-house-readies-new-message-nation-n1232884


...and then there is uplisting, trial results, Mexico, BLA, etc.

Shorts will be very nervous next week.

 

 

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities